Sinopharm Group Co. Ltd. (1099.HK)
HKD 21.45
(-1.15%)
HKD 21.45
(-1.15%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 26.89 Billion CNY | -1.67% |
| 2022 | 26.24 Billion CNY | 7.24% |
| 2021 | 24.68 Billion CNY | 7.87% |
| 2020 | 22.61 Billion CNY | 9.24% |
| 2019 | 20.31 Billion CNY | 26.19% |
| 2018 | 16.67 Billion CNY | 34.51% |
| 2017 | 13.43 Billion CNY | 15.4% |
| 2016 | 12.03 Billion CNY | 14.95% |
| 2015 | 10.12 Billion CNY | 17.59% |
| 2014 | 8.61 Billion CNY | 28.48% |
| 2013 | 6.7 Billion CNY | 19.03% |
| 2012 | 5.9 Billion CNY | 24.53% |
| 2011 | 4.43 Billion CNY | 48.38% |
| 2010 | 3.04 Billion CNY | 51.32% |
| 2009 | 2.01 Billion CNY | 32.82% |
| 2008 | 1.51 Billion CNY | 37.05% |
| 2007 | 1.1 Billion CNY | 86.79% |
| 2006 | 592.22 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | - CNY | -100.0% |
| 2023 Q4 | 13.49 Billion CNY | 213.22% |
| 2023 FY | - CNY | -1.67% |
| 2023 Q3 | 4.3 Billion CNY | -60.5% |
| 2023 Q2 | 10.9 Billion CNY | 0.0% |
| 2022 Q4 | 8.49 Billion CNY | 70.92% |
| 2022 FY | - CNY | 7.24% |
| 2022 Q2 | 10.55 Billion CNY | 0.0% |
| 2022 Q3 | 4.96 Billion CNY | -52.92% |
| 2021 FY | - CNY | 7.87% |
| 2021 Q4 | 12.83 Billion CNY | 0.0% |
| 2021 Q2 | 10.05 Billion CNY | 0.0% |
| 2020 FY | - CNY | 9.24% |
| 2020 Q2 | 8.39 Billion CNY | 0.0% |
| 2020 Q4 | 12.48 Billion CNY | 0.0% |
| 2019 Q4 | 10.85 Billion CNY | 0.0% |
| 2019 Q2 | 9.04 Billion CNY | 0.0% |
| 2019 FY | - CNY | 26.19% |
| 2018 Q2 | 7.83 Billion CNY | 0.0% |
| 2018 FY | - CNY | 34.51% |
| 2018 Q4 | 8.84 Billion CNY | 0.0% |
| 2017 Q1 | 2.8 Billion CNY | -48.4% |
| 2017 Q4 | 7.9 Billion CNY | 0.0% |
| 2017 FY | - CNY | 15.4% |
| 2017 Q2 | 6.35 Billion CNY | 126.76% |
| 2016 Q4 | 5.43 Billion CNY | 0.0% |
| 2016 FY | - CNY | 14.95% |
| 2016 Q2 | 5.72 Billion CNY | 0.0% |
| 2015 FY | - CNY | 17.59% |
| 2015 Q4 | 5.05 Billion CNY | 0.0% |
| 2015 Q2 | 5.06 Billion CNY | 0.0% |
| 2014 FY | - CNY | 28.48% |
| 2014 Q2 | 4.27 Billion CNY | 0.0% |
| 2014 Q4 | 4.33 Billion CNY | 0.0% |
| 2013 Q2 | 3.31 Billion CNY | 0.0% |
| 2013 Q4 | 3.39 Billion CNY | 0.0% |
| 2013 FY | - CNY | 19.03% |
| 2012 Q4 | 1.42 Billion CNY | 18.94% |
| 2012 FY | - CNY | 24.53% |
| 2012 Q3 | 1.19 Billion CNY | 0.0% |
| 2012 Q2 | 1.19 Billion CNY | 0.0% |
| 2012 Q1 | 1.19 Billion CNY | 0.0% |
| 2011 Q4 | 1.19 Billion CNY | 30.21% |
| 2011 Q3 | 919.82 Million CNY | 0.0% |
| 2011 Q1 | 919.82 Million CNY | 0.0% |
| 2011 Q2 | 919.82 Million CNY | 0.0% |
| 2011 FY | - CNY | 48.38% |
| 2010 Q2 | 606.37 Million CNY | 0.0% |
| 2010 FY | - CNY | 51.32% |
| 2010 Q1 | 606.37 Million CNY | 0.0% |
| 2010 Q3 | 606.37 Million CNY | 0.0% |
| 2010 Q4 | 919.82 Million CNY | 51.69% |
| 2009 Q4 | 606.37 Million CNY | 44.95% |
| 2009 FY | - CNY | 32.82% |
| 2009 Q2 | 418.34 Million CNY | 0.0% |
| 2009 Q3 | 418.34 Million CNY | 0.0% |
| 2009 Q1 | 418.34 Million CNY | 0.0% |
| 2008 FY | - CNY | 37.05% |
| 2008 Q4 | 418.34 Million CNY | 10.37% |
| 2008 Q3 | 379.02 Million CNY | 0.0% |
| 2008 Q2 | 379.02 Million CNY | 0.0% |
| 2008 Q1 | 379.02 Million CNY | 0.0% |
| 2007 Q2 | 276.55 Million CNY | 0.0% |
| 2007 Q3 | 276.55 Million CNY | 0.0% |
| 2007 Q4 | 379.02 Million CNY | 37.05% |
| 2007 FY | - CNY | 86.79% |
| 2007 Q1 | 276.55 Million CNY | 0.0% |
| 2006 Q3 | 148.05 Million CNY | 0.0% |
| 2006 Q4 | 276.55 Million CNY | 86.79% |
| 2006 FY | - CNY | 0.0% |
| 2006 Q1 | 148.05 Million CNY | 0.0% |
| 2006 Q2 | 148.05 Million CNY | 0.0% |
| 2005 Q4 | 148.05 Million CNY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Wanjia Group Holdings Limited | -29.02 Million HKD | 92775.183% |
| China Health Group Limited | -37.41 Million HKD | 71985.865% |
| Tai United Holdings Limited | -1.18 Billion HKD | 2369.605% |